Profile
Corporate information
Official name
Nagi Bioscience SA
Official name
Nagi Bioscience SA
Investment activity status
Active investor
Overview
EPFL spin-off Nagi Bioscience has developed a device that allows rapid toxicology testing of new chemicals. It offers whole organism tests without falling under the animal test ban. The model organism, the 1mm worm C. elegans is introduced into the device on microfluidic chips. The device is able to measure different parameters for a large number of tests that run in parallel, a very effective and easy setup. Nagi sells its device to companies in the agrochemicals, cosmetics and pharma industries.
Funding
Funding rounds
Change in valuation: unknown
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Verve Capital Partners AG | Switzerland | Initial investment. Round participant. |
Change in valuation: unknown
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Zurich Cantonal Bank | Switzerland | Initial investment. Round participant. |
Cap Table
Current and past shareholders
| Investor | Round | |
|---|---|---|
|
|
Verve Capital Partners AG |
N/A |
|
|
Zurich Cantonal Bank |
N/A |